Abstract: Prothrombinase-induced clotting time (PiCT) is proposed as a rapid and inexpensive laboratory test to measure direct oral anticoagulant (DOAC) drug levels. In a prospective, multicenter cross-sectional study, including 851 patients, we aimed to study the accuracy of PiCT in determining rivaroxaban, apixaban, and edoxaban drug concentrations and assessed whether clinically relevant drug levels could be predicted correctly. Citrated plasma samples were collected, and the Pefakit((R)) PiCT was utilized. Ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to measure drug concentrations. Cut-off levels were established using receiver-operating characteristics curves. We calculated sensitivities and specificities with respect to clinically relevant drug concentrations. Spearman's correlation coefficient between PiCT and drug concentrations was 0.85 in the case of rivaroxaban (95% CI 0.82, 0.88), 0.66 for apixaban (95% CI 0.60, 0.71), and 0.78 for edoxaban (95% CI 0.65, 0.86). The sensitivity to detect clinically relevant drug concentrations was 85.1% in the case of 30 microg L(-1) (95% CI 82.0, 87.7; specificity 77.9; 72.1, 82.7), 85.7% in the case of 50 microg L(-1) (82.4, 88.4; specificity 77.3; 72.5, 81.5), and 85.1% in the case of 100 microg L(-1) (80.9, 88.4; specificity 73.2%; 69.1, 76.9). In conclusion, the association of PiCT with DOAC concentrations was fair, and the majority of clinically relevant drug concentrations were correctly predicted.
Tags: analysis, the decision to publish, or manuscript preparation. MN reports research, and from Alexion Pharma GmbH, all outside the submitted work. JDS reports lecture, and honoraria for participating in scientific advisory boards from Bayer, Pfizer,, apixaban, cross-sectional studies, CSL-Behring, Novartis, Novo Nordisk, Roche, Sobi, and Takeda. WAW reports, diagnostic accuracy, direct oral anticoagulants, edoxaban, fees and advisory honoraria from Bayer Healthcare, Pfizer, Takeda, Siemens, and, from Bayer Healthcare, and Daiichi Sankyo. LA reports research grants from Bayer,, grants from Bayer Healthcare, outside of the submitted work, lecture honoraria, laboratory monitoring, Pentapharm. These companies had no role in study design, data collection and, prothrombinase-induced clotting time, research grants from Bayer Healthcare, BMS-Pfizer, Daiichi Sankyo, and Sanofi,, rivaroxaban, Sanofi., sensitivity and specificity, substances: Bayer Healthcare AG, Bristol-Myers Squibb, Daiichi Sankyo, and.